Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464766 | 1.00 | KMT2A (0.37) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL20113215 | 1.00 | KMT2A (0.37) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL4886758 | 0.81 | POLB (0.43) | KMT2AMEN1ATMALDH1A1LMNA | |
| SCHEMBL4886754 | 0.81 | POLB (0.43) | KMT2AMEN1ATMALDH1A1LMNA | |
| SCHEMBL7306693 | 0.81 | KMT2A (0.36) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL7302241 | 0.81 | KMT2A (0.36) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL26078627 | 0.81 | KMT2A (0.36) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL14288714 | 0.81 | MMP2 (0.42) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL7308325 | 0.81 | KMT2A (0.36) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL16367126 | 0.81 | KMT2A (0.36) | KMT2AMEN1ATMMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | SALAMA ZOSER B | 2008-07-24 | — | — | US | claimed |
| WO-2022078462-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| EP-1765328-B1 | ANTI-CANCER COMPOSITION COMPRISING PROLINE OR ITS DERIVATIVES AND AN ANTI-TUMOUR ANTIBODY | SALAMA ZOSER B (DE) | 2011-11-23 | — | — | EP | disclosed |
| US-7727530-B2 | Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody | SALAMA ZOSER B | 2010-06-01 | — | — | US | disclosed |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | SALAMA ZOSER B | 2008-07-24 | — | — | US | disclosed |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | SALAMA ZOSER B | 2008-07-24 | — | — | US | disclosed |
| US-20050276810-A1 | Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody | SALAMA ZOSER B | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | PREP, PRAP1, VHL | KMT2A 2637/4885MEN1 660/4885ATM 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.